DUBLIN--(BUSINESS WIRE)--The "Malignant Glioma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
Glioma clinical trials report provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions.
The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.
Major drugs under development in Glioma are provided in the report along with their details of mechanism of action, route of administration, target, therapy, molecule and class.
Scope of the Report:
- Number of Glioma clinical trials across regions - Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Glioma
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
Leading sponsors of Glioma clinical trials worldwide are listed
Key Topics Covered:
1 Table of Contents
2 Executive Summary
3 Malignant Glioma Drugs in Ongoing and Completed Trials
4 Global Malignant Glioma Clinical Trial Research Trends
5 Europe Malignant Glioma Clinical Trial Research Trends
6 North America Malignant Glioma Clinical Trial Research Trends
7 South and Central America Malignant Glioma Clinical Trial Research Trends
8 South East Asia Malignant Glioma Clinical Trial Research Trends
9 Western Pacific Malignant Glioma Clinical Trial Research Trends
10 Recent Clinical Trials - Snapshots
For more information about this report visit https://www.researchandmarkets.com/research/n5flhv/malignant_glioma?w=4